28 June 2023 - NICE has published final evidence-based recommendations on the use of deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis.

Deucravacitinib is recommended as an option for the treatment of adults with moderate to severe plaque psoriasis only if:

• The Psoriasis Area and Severity Index score is 10 or more and the Dermatology Life Quality Index score is more than 10
• The condition has not responded to other systemic treatments, including cyclosporin, methotrexate and phototherapy, or these options are contra-indicated or not tolerated
• BMS provides deucravacitinib according to the commercial arrangement

Read NICE technology appraisal guidance